IQopta ApS
IQ opta provides an AI layer that integrates directly into existing medical imaging workflows, accelerating image analysis from drug development to clinical routine. The platform focuses on nuclear medicine and radiopharmaceutical drug development, embedding AI-powered analysis into tools clinicians and researchers already use. Demos are shared under mutual NDA to protect underlying intellectual property.
- Healthcare Technology
- Artificial Intelligence
- Digital Health
- Drug Discovery & Therapeutics
- Software Only
- Data & Analytics
Funding
Founders
Founder details are not available yet.
Product
Problem
Image analysis is a recurring bottleneck across the full lifecycle from drug development to clinical routine, throttling scientific progress and adding delays to workflows that depend on medical imaging. Clinicians and researchers are often forced to learn new, specialized software, which slows adoption and reduces efficiency.
Solution
IQ opta provides an AI layer that accelerates existing medical imaging workflows by operating underneath the tools clinicians and researchers already trust. Rather than building yet another standalone piece of software, IQ opta integrates AI-powered analysis directly into established workflows, enabling faster and smarter medical image analysis. The platform is designed to support the full lifecycle from drug development to clinical routine, with a particular focus on nuclear medicine and radiopharmaceutical drug development. By embedding AI into familiar tools, IQ opta removes the need for specialists to learn new systems while improving the speed and quality of image interpretation. The company collaborates with leading academic groups and industry partners to ensure the technology addresses real-world clinical needs.
Target Audience
Primary customers are clinicians, researchers, and industry partners in nuclear medicine and radiopharmaceutical drug development, as well as academic groups and life-science organizations that rely on medical imaging in their workflows.
Features
- AI layer that integrates with existing medical imaging workflows rather than replacing them
- Focus on nuclear medicine and radiopharmaceutical drug development applications
- AI-powered analysis tools designed to accelerate image interpretation and reduce bottlenecks
- Cloud-based AI processing delivered through third-party providers including Amazon Web Services (AWS) AI
- Collaboration with leading academic groups and industry partners across nuclear medicine
- Demos shared under mutual NDA to protect underlying intellectual property